Does Cholestyramine Light Interact with Maralixibat Chloride?
CDI records a moderate classification for Cholestyramine Light and Maralixibat Chloride. The stored summary is: Bile acid binding resin may bind to maralixibat in the gut. Administer LIVMARLI at least 4 hours before or after cholestyramine. The mechanism involves bile acid binding in the gut. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Cholestyramine Light Class
- Bile Acid Sequestrant
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Bile acid binding in the gut
What To Tell Your Doctor or Pharmacist
If you are taking Cholestyramine Light and your doctor is considering prescribing Maralixibat Chloride (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider